Sarcoidosis
189
25
28
101
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
14 trials with published results (7%)
Research Maturity
101 completed trials (53% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.3%
10 terminated out of 189 trials
91.0%
+4.5% vs benchmark
11%
21 trials in Phase 3/4
14%
14 of 101 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 101 completed trials
Clinical Trials (189)
Corticosteroid Tapering in Sarcoidosis
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD
Immunological Mechanisms in Sarcoidosis
Virtual Patient Groups for Sarcoidosis Associated Fatigue
MoMa Signature During Granulomatosis
Rheumatology Patient Registry and Biorepository
Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension
Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis
Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Institutional Registry of Rare Diseases
Cell Free DNA in Cardiac Sarcoidosis
Vitamin D Homeostasis in Sarcoidosis
Worldwide Sarcoidosis Research Study
Full-Field Optical Coherence Tomography (FFOCT) for Evaluation of Bronchoscopic Small Biopsy Specimens
Medication Adherence in Patients With Sarcoidosis
Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes
Efficacy and Safety of Influenza Vaccine During Sarcoidosis
Interstitial Lung Disease Research Unit Biobank
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)